

Index

Note: Page numbers of article titles are in **boldface** type.

- AGGLUTINATION tests, in antigen detection, 55-56
- Alloimmunization, in transfusion therapy, 70, 72
- Anisotropy, angular, in light scattering, 98-99
- Antibody(ies), monoclonal, as reagents, 99-105
- Antigen, detection of, by immunologic technique, 49-65
- Assay(s). See under specific types.
- BAYES' theorem**, in assessment of laboratory diagnostic technology, 11-12, 27-32
- Benefit-risk analysis, in clinical decision making, 25-26
- "Big-ticket" technology, assessment of, 7-8
- Blood bank(s), current technology, 67-76
- Blood cell(s). See *Erythrocyte(s)* or *Leukocyte(s)*.
- Blood products, inventory management, 67-76
- Blood transfusion. See *Erythrocyte transfusion*; *Platelet transfusion*; *Transfusion*
- Break-even analysis, in laboratory technology assessment, 44-45
- CAPITAL investment**, in laboratory technology assessment, 41
- Case-finding, definition of, 24
- Chemical methods, in antigen detection, 63-64
- Chemiluminescence immunoassay, methods of, 98-101
- Coagglutination, in antigen detection, 55-56
- Computer information systems, in laboratory, assessment of, 111-125
- Computerized axial tomography (CAT), assessment of, 7
- Cost analysis, in assessing computer systems, 118-120
- in assessing laboratory technology, 39-47
- in assessing medical technology, 4-5, 13-14, 35
- Cost-benefit model, in therapeutic decision-making. See *Threshold approach*.
- Counterimmunoelectrophoresis, in antigen detection, 53-55
- Crossmatching, antiglobulin, evaluation of, 74
- DATA**, storage, in laboratory, 111-125
- Decision analysis, clinical, 22-26
- in selection of computer system, 117-123
- Discounting, of cash flows, 45-46
- ECONOMIC analysis**, in laboratory technology assessment, 39-47
- Education, in use of laboratory technology, 13-17
- Efficiency, of laboratory test, 31-32
- Enzyme-channeling immunoassay, homogeneous, 96
- Enzyme immunoassays, 80-88
- future potential of, 96-97
- heterogeneous, 81-86
- homogeneous, 86-88
- thermistor analysis in, 99
- Enzyme-linked immunosorbent assay (ELISA), in microbial antigen detection, 58-60
- Erythrocyte(s), frozen, transfusion of, 70
- leukocyte-poor, transfusion of, 69-70
- transfusion of, 68-71
- washed, transfusion of, 70
- FLOW-ANALYSIS technology**, in leukocyte differential counting, 127-150
- Fluorescent antibody technique, in antigen detection, 50-53
- Fluoroimmunoassay(s), 88-91
- future potential of, 97
- heterogeneous, 88-90
- homogeneous, 90-95
- Fluorometer, types of, 90
- GAS chromatography**, in microbial antigen detection, 63-64
- Granulocyte(s), transfusion of, 72-72

- HEMATOLOGY, technology assessment in, 127-150
- Hepatitis B surface antigen, detection of, 53, 57-58, 60
- Hybridoma method, in production of monoclonal antibodies, 99-105
- IMMUNOASSAYS, enzyme, 80-88
light scattering, 78-79
technology of, 77-109
- Immunofluorescence assay(s), versus fluoroimmunoassay, 88-89
direct, in antigen detection, 50-53
- Immunologic methods, in microbial antigen detection, 50-63
- Immunology, clinical, technology assessment in, 77-109
- Immunoperoxidase, direct, in antigen detection, 52
- Infectious disease, immunologic diagnostic techniques, 49-65
- Information systems, laboratory, assessment of, 111-125
- LABORATORY. See also *Laboratory medicine*.
clinical, role in technology assessment (chart), 16
computer-based information systems in, assessment of, 111-125
methods, assessing clinical utility of, 21-37
microbiology, immunologic diagnostic methods in, 49-65
technology. See also *Technology* and under specific procedures.
cost analysis, 4-5, 13-14, 35, 39-47, 118-120
- Laboratory medicine, technology assessment in, 3-19
symposium on, 1-150
- Laboratory tests, assessing clinical utility of, 21-37
benefit-risk analysis in, 25-26
in clinical decision-making, 11, 22-24
monitoring as rationale for, 10
physicians' patterns of use, 9-12
"threshold approach" to, 11, 26, 32-35
- Latex agglutination test, in antigen detection, 55-56
- Legionella pneumophila, detection of, 51
- Legionnaires' disease, diagnosis of, 51
- Leukocyte(s), differential count, automation by flow-analysis, 127-150
- Leukocyte-poor red blood cells, transfusion of, 69-70
- Light scattering assays, 78-79
"Little-ticket" technology, assessment of, 7-8
- MASS spectrometry-gas chromatography, in antigen detection, 63-64
- Microbial antigen, detection by immunologic technique, 49-65
- Medical technology. See *Laboratory, technology*.
- Microbiology, clinical, microbial antigen detection and, 49-65
- Microcomputers, in laboratory, 115
- Monitoring, patient, use of laboratory tests for, 9-10
- Monoclonal antibodies, as reagents, 99-105
- NEPHELOMETRIC assay, 78-79
- PARTICLE aggregation assays, 79
- Pheresis, technology of, 71-72
- Plasma, components of, 73
fresh frozen, transfusion, 68-69
- Platelet transfusion, 71-72
- Pneumocystis carinii* antigen, detection of, 54
- Predictive value, in laboratory testing, 27-32
- Present value, of cash flows, 45-46
- Prevalence, effect of on predictive value, 11, 28-29
- Profiling, definition of, 24
- RADIOIMMUNOASSAY, in antigen detection, 56-58
- Reagent(s), interchangeability of, 80-81
monoclonal antibodies as, 99-105
- Receiver-Operator-Characteristic (ROC) curve, 31-32, 34
- Red blood cells. See *Erythrocyte(s)*.
- Regulation, congressional, of medical technology, 5-7
executive, of medical technology, 6-7, 9
- Rotavirus gastroenteritis, detection by ELISA, 59
- SCREENING, definition of, 24
- Sensitivity, of immunologic methods, 61
of laboratory test, 8, 11, 27-28
- Serologic techniques, in blood banking, 73-75
- Specificity, of immunologic methods, 60-61
of laboratory test, 11, 27-28
- Streptococcal infection, diagnosis of, 51
- TECHNOLOGY, computer, in laboratory medicine, assessment of, 111-125
flow-analysis, in leukocyte differential counting, 127-150
in clinical immunology, assessment of, 77-109
laboratory, assessment of, 3-19
symposium on, 1-150
cost analysis, 4-5, 13-14, 35, 39-47, 118-120
microbiologic, assessment of, 49-65
of blood banking, 67-76
of immunoassays, 77-109

Testing, laboratory. See *Laboratory tests*.
Thermistor analysis, in enzyme immunoassay,
99
Threshold approach, in therapeutic decision-
making, 11, 26, 32-35
Transfusion, of blood products, 67-76
Turbidimetric assay, 78-79

VIRUS, detection by immunologic technique,
52, 55

WHITE blood cells. See *Leukocyte(s)*.